Immunogenicity, Efficacy, and Safety of Biosimilar Insulin Glargine (Gan & Lee Glargine) Compared With Originator Insulin Glargine (Lantus) in Patients With Type 1 Diabetes After 26 Weeks Treatment.

OBJECTIVE: To compare the immunogenicity, safety, and efficacy of Gan & Lee insulin glargine (GL Glargine) with that of the originator insulin glargine (Lantus) in patients with type 1 diabetes mellitus (T1DM). METHODS: This was a phase 3, multicenter, randomized, open-label, equivalence study. Five hundred seventy-six subjects with T1DM were randomized 1:1 to receive either GL Glargine or Lantus treatment for 26 weeks. The primary end point was the percentage of subjects in each treatment group who developed treatment-induced anti-insulin antibody after baseline and up to visit week 26, which was evaluated using a country-adjusted logistic regression model. The study also compared the changes in glycated hemoglobin, and adverse events including hypoglycemia. RESULTS: The percentage of subjects positive for treatment-induced anti-insulin antibody by Week 26 was 25.8% in the GL Glargine treatment group and 25.3% in the Lantus treatment group, with a 90% confidence interval (-5.4, 6.5) of the difference in proportions that fell completely between the similarity margins (-11.3, 11.3). The least squares mean difference between treatment groups for changes in glycated hemoglobin was -0.08 (90% confidence interval: -0.23, 0.06), and the other immunogenicity and safety profiles were comparable. CONCLUSION: GL Glargine demonstrated similar immunogenicity, efficacy, and safety compared to Lantus over 26 weeks in patients with T1DM.

[Optic neuropathy in diabetic patients]. / Neuropatia peczka wzrokowego u chorych na cukrzyce.

INTRODUCTION: Diabetes beyond the well described diabetic retinopathy symptoms leads also to other ophthalmology problems. Among them, there are less known neuropathies and other neuroophthalmological disorders. To determine whether optic neuropathy coexists with painful peripheral neuropathy. MATERIALS AND METHODS: 50 patients (99 eyes) with diabetes (type one 21 patients and type two 29 patients) and painful neuropathy. Their mean age was 56.14 +/- 11.31 standard deviation (SD) and their glycosylated hemoglobin (HbA1c) was 8.12 +/- 1.46 SD. Mean duration of diabetes was 17.05 +/- 9.47 SD. 50 healthy (100 eyes) age- and sex-matched individuals were evaluated as a control group. In all patients the basic ophthalmological exam was performed. Visual field was tested with Humphrey perimeter (Carl Zeiss Meditec HFA II 745); the mean defect (MD) and pattern standard deviation (PSD) parameters were counted. Optic disc tomography was determined by Heidelberg retina tomograph II; the cup/disk area ratio (C/D) and mean retinal nerve fiber layer (RNFL) thickness were considered. RESULTS: Diabetic eyes had significantly lower results of MD and RNFL thickness. Mean MD = -8.83 +/- 8.5 SD and mean RNFL thickness = 0.29 +/- 0.13 SD whereas PSD = 4.1 +/- 3.27 SD significantly different values (p < 0.001; p < 0.05; p < 0.05 respectively). There was no statistically significant increase in C/D = 0.24 +/- 0.14 SD versus control subjects (p = 0.1). We observed general reduction of retinal sensitivity and glaucoma-like changes in visual field as vell as diminished mean RNFL thickness. CONCLUSIONS: The results of our study suggest that in diabetic patients with peripheral painful neuropathy not only peripheral nerves but also optic nerve are damaged.